Novel epigenetic therapies in hematological malignancies: Current status and beyond. (2018)
Attributed to:
Characterising and targeting aberrant enhancer function in acute myeloid leukaemia (AML)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.semcancer.2017.07.005
PubMed Identifier: 28782607
Publication URI: http://europepmc.org/abstract/MED/28782607
Type: Journal Article/Review
Volume: 51
Parent Publication: Seminars in cancer biology
ISSN: 1044-579X